In recent years, immune checkpoint inhibitors targeted at ﻿programmed death-1(PD-1)/ ﻿programmed death-ligand 1 (PD-L1) pathway have shown antitumor activity in multiple tumor types [7, 8]. The gene discussed is CD274; the disease is neoplasm.